Autolus Therapeutics (NASDAQ:AUTL) Now Covered by HC Wainwright

HC Wainwright began coverage on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research report report published on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $9.00 price objective on the stock. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.04) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.64) EPS and FY2030 earnings at ($0.24) EPS.

Other research analysts have also issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, January 21st. Zacks Research cut shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 21st. Wall Street Zen downgraded shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Finally, Needham & Company LLC decreased their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, January 12th. Five investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $8.50.

Autolus Therapeutics Stock Up 7.9%

Autolus Therapeutics stock opened at $1.51 on Tuesday. The business has a 50 day moving average price of $1.57 and a two-hundred day moving average price of $1.57. Autolus Therapeutics has a 12 month low of $1.11 and a 12 month high of $2.70. The stock has a market cap of $401.87 million, a price-to-earnings ratio of -1.82 and a beta of 1.98.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds have recently made changes to their positions in the company. Armistice Capital LLC boosted its holdings in shares of Autolus Therapeutics by 9.1% in the 2nd quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock worth $27,360,000 after acquiring an additional 1,000,000 shares in the last quarter. TFG Asset Management GP Ltd raised its position in Autolus Therapeutics by 10.5% in the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after purchasing an additional 900,000 shares during the last quarter. Cetera Investment Advisers boosted its stake in Autolus Therapeutics by 17.6% in the second quarter. Cetera Investment Advisers now owns 617,172 shares of the company’s stock worth $1,407,000 after purchasing an additional 92,300 shares in the last quarter. R Squared Ltd acquired a new position in Autolus Therapeutics in the second quarter worth $50,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Autolus Therapeutics during the second quarter worth $1,288,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.